Belvedere Trading
MACK

Belvedere Trading’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Belvedere Trading’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-37,100
Closed -$456K – 1268
2023
Q1 		$456K Buy
37,100
+2,700
+8% +$31.7K ﹤0.01% 162
2022
Q4 		$394K Buy
+34,400
New +$283K ﹤0.01% 169

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Belvedere Trading's MACK Position: Q2 2023 in Review

Belvedere Trading sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2023, closing a stake of 10,888 shares — an estimated $134K sold.

Belvedere Trading first reported a position in MACK in Q3 2022 and held it in 3 quarters. The position peaked at $447K in Q4 2022. 62 funds tracked by Wall St. Rank hold MACK as of Q2 2023.

  • Belvedere Trading reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 10,888 Merrimack Pharmaceuticals, Inc. shares in Q2 2023, an estimated $134K.
  • Belvedere Trading first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2022 and held it in 3 quarters.
  • Belvedere Trading's Merrimack Pharmaceuticals, Inc. position peaked at $447K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.